In 2019, the total value of sensors and apps in the global digital respiratory devices market stood at some 12.6 million U.S. dollars. By 2030, sensors and apps were forecast to be worth approximately 127 million U.S. dollars.

Digital Respiratory Devices market to grow at a significant CAGR of 27.31% and projected to reach $405.1 Million during 2021-2030. BIS Research provides deep market insight, industry analysis, trends & forecast to 2030.

In 2019, the value of the digital respiratory devices market in North America amounted to 7.6 million U.S. dollars, by 2030 this value was forecast to increase to 185.4 million U.S. dollars. Similarly large growth was forecast in other regions around the world as well, with the market size in Europe forecast to increase from 3.4 million U.S. dollars in 2019 to 116.1 million U.S. dollars in 2030.

The size and share of the market is categorized based on Application (Smart Inhalers and Nebulizers, Chronic Obstructive Pulmonary Disease (COPD), Other) and Product (Sensors, Smart Inhalers, Nebulizers, Other) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Report Covers Italy Respiratory Therapeutic Devices Market Share and is Segmented by Type (Diagnostic and Monitoring Devices, Therapeutic Devices, and Disposables). The report offers market size and forecast values in USD million for the above segments.

The North America Digital Respiratory Devices report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

The Asia-Pacific Digital Respiratory Device Market is projected to grow at a CAGR of around 36.2% during the forecast period 2023-28.

The size of the Italy Digital Respiratory Devices Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 6.80% during the forecast period. The Italian market for digital respiratory devices is expanding steadily, driven by growing asthma, COPD, and sleep apnea incidence. Demand for novel digital respiratory devices is expected to benefit from healthcare delivery systems evolving towards more digital solutions in the networks of healthcare providers. The significant drivers in this market include the technological advancements that will fuel the development of connected devices, including smart inhalers, digital nebulizers, and remote monitoring systems, all which may have integral features for the immediate transmission and sharing of real-time data to enhance patient engagement and inform healthcare provider decisions. The growing interest in telemedicine more broadly and additionally due to the COVID-19 pandemic has also boosted the development of digital respiratory solutions. Patients more and more prefer being treated at home rather than at hospitals, which boosts demand for apparatus enabling remote management of such conditions. Government initiatives and health care policies for the improvement of respiratory health and control of chronic diseases are adding to the growth of the market. The health care infrastructure of Italy is well-developed, as advanced technology is being provided to patients, and growth in the healthcare innovation sector increases the development of new digital solutions. In general, the Italy digital respiratory devices market is expected to continue growing further, with much commitment toward improving outcomes of patients through innovative technology. Therefore, with growing awareness of respiratory health and digital solutions becoming increasingly more integrated into healthcare practices, demand for effective digital respiratory devices is poised to increase. Recent developments include: In July 2022, the Bastide Group announced the purchase of a majority stake in Oxystore, an Italian company near Milan. Oxystore specializes in consumer home diagnosis and online sales of oxygen therapy and sleep apnea devices. It also provides support and follow-up services to patients receiving home treatment., In February 2022, ProSomnus Sleep Technologies, one of the leaders in patient-preferred medical devices for the treatment of obstructive sleep apnea (OSA), displayed four poster abstracts of its oral appliance therapy (OAT) devices at the World Sleep Congress 2022, which was held in March 2022, in Rome, Italy.. Key drivers for this market are: Increasing Prevalence of Respiratory Disorders, Technological Advancements and Increasing Applications in Homecare Settings. Potential restraints include: High Cost of Devices. Notable trends are: Ventilators as Therapeutic Devices Expected to Register Significant Growth.

Global Digital Respiratory Device Market to grow from US$ 46.93 Billion in 2023 to US$ 448.33 Billion by 2032, at a CAGR of 28.5%.

According to Cognitive Market Research, the global digital dose inhaler market size will be USD 19246 million in 2025. It will expand at a compound annual growth rate (CAGR) of 19.80% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 7121.02 million in 2025 and will grow at a compound annual growth rate (CAGR) of 18.1% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5581.34 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 4619.04 million in 2025 and will grow at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 731.35 million in 2025 and will grow at a compound annual growth rate (CAGR) of 20.6% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 769.84 million in 2025 and will grow at a compound annual growth rate (CAGR) of 21.2% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 423.41 million in 2025 and will grow at a compound annual growth rate (CAGR) of 20.1% from 2025 to 2033.
COPD (chronic obstructive pulmonary disease) category is the fastest growing segment of the digital dose inhaler industry

Market Dynamics of Digital Dose Inhaler Market

Key Drivers for Digital Dose Inhaler Market

Growing Demand for Technology-Enabled Features of Respiratory Devices to Boost Market Growth

The growing demand for technology-enabled features in respiratory devices is a key driver of the digital dose inhaler market. Patients and healthcare providers are increasingly adopting smart inhalers equipped with sensors, Bluetooth connectivity, and mobile app integration to enhance treatment adherence and monitoring. These inhalers provide real-time data tracking, medication reminders, and usage analytics, improving disease management for conditions like asthma and COPD. Additionally, the rise of telemedicine and remote patient monitoring is driving the need for connected devices that allow physicians to track inhaler use and adjust treatment plans accordingly. The demand for personalized healthcare solutions, coupled with advancements in AI, IoT, and cloud computing, is further accelerating market growth. In September 2020, Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., introduced of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, 2 digital maintenance inhalers for patients with asthma.

https://www.tevapharm.com/news-and-media/latest-news/teva-launches-two-digital-inhalers-in-the-u.s.-airduo-digihaler-fluticasone-propionate-and-salmeterol

Increasing Emphasis on Managing Chronic Respiratory Disease to Boost Market Growth

The increasing emphasis on managing chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) is a key driver for the digital dose inhaler market. Rising air pollution, smoking habits, and occupational hazards contribute to the growing prevalence of these conditions. Digital dose inhalers improve patient adherence by providing real-time monitoring, dose tracking, and connectivity to healthcare providers via mobile applications. Governments and healthcare organizations are actively promoting digital health solutions, further accelerating market growth. Additionally, the ageing population, which is more susceptible to respiratory ailments, is driving demand for user-friendly, efficient inhalers. As awareness and adoption of digital healthcare technologies rise, digital dose inhalers are becoming essential tools for improving disease management and patient outcomes.

Restraint Factor for the Digital Dose Inhaler Market

High Development Cost Will Limit Market Growth

The high development cost is a major restraint in the digital dose inhaler market. Developing these inhalers involves advanced technology, including sensors, Bluetooth connectivity, and dose-tracking features, which significantly increase research and production expenses. Pharmaceutical companies must invest heavily in R&D to ensure accuracy, safety, and regulatory compliance, leading to higher manufacturing costs. These costs are ultimately pass...

The Global COPD and Asthma Devices Market is experiencing robust growth, driven by rising prevalence of respiratory diseases, an aging global population, and increasing healthcare expenditure. Technological advancements in inhaler design, such as smart inhalers with medication adherence tracking, and the development of novel therapies are further fueling market expansion. The market is segmented by device type (e.g., inhalers, nebulizers, spacers) and application (e.g., home use, hospital use), offering diverse opportunities for manufacturers. While the market faces restraints like high treatment costs and potential side effects associated with certain medications, the overall outlook remains positive, particularly in developing economies with burgeoning healthcare infrastructure and increased awareness about respiratory health. Competition is intense, with established players like Consort Medical, Gerresheimer, NYPRO, Philips Healthcare, and RPC Bramlage vying for market share through product innovation and strategic partnerships. Regional growth varies, with North America and Europe currently dominating due to higher prevalence rates and advanced healthcare systems. However, Asia-Pacific is expected to witness significant growth in the coming years due to rising respiratory disease incidence and increasing disposable incomes. The forecast period (2025-2033) anticipates continued expansion, with the CAGR significantly influencing the market value. Growth will be fuelled by increasing investment in research and development, leading to the introduction of more effective and user-friendly devices. Furthermore, government initiatives aimed at improving respiratory healthcare access, especially in underserved populations, will further stimulate market growth. While pricing pressures and regulatory hurdles may pose challenges, the increasing demand for effective respiratory disease management solutions is expected to outweigh these factors, ensuring a consistent upward trajectory for the Global COPD and Asthma Devices Market. Companies are focusing on improving device ergonomics, incorporating digital health technologies, and tailoring solutions to meet specific patient needs to secure their position in this dynamic and ever-evolving market.

The market is mainly propelled by the rising pollution levels, growing number of smokers, and the aging population suffering from lung diseases. And developments in inhaler technology, like digital-tracking smart inhalers, are making treatment more convenient and efficient. It is projected to be growing at a CAGR of 4.5% by 2025, reaching USD 40.99 Billion and in 2035, it will reach USD 63.66 Billion.

Metric	Value
Market Size (2025E)	USD 40.99 Billion
Market Value (2035F)	USD 63.66 Billion
CAGR (2025 to 2035)	4.5%

Country-wise Insights

Country	CAGR (2025 to 2035)
USA	4.8%

Country	CAGR (2025 to 2035)
UK	4.4%

Country	CAGR (2025 to 2035)
European Union (EU)	4.5%

Country	CAGR (2025 to 2035)
Japan	4.7%

Country	CAGR (2025 to 2035)
South Korea	4.8%

Competitive Outlook

Company Name	Estimated Market Share (%)
GlaxoSmithKline plc (GSK)	15-20%
AstraZeneca plc	12-16%
Boehringer Ingelheim International GmbH	10-14%
Teva Pharmaceutical Industries Ltd.	8-12%
Novartis AG	5-9%
Other Companies (combined)	40-50%

Market Size and Growth: The Japan respiratory devices market size was valued at XX million in 2025 and is projected to expand at a CAGR of 9.60% from 2025 to 2033. This growth is driven by factors such as the increasing prevalence of respiratory diseases, aging population, and technological advancements. Diagnostic and monitoring devices hold a significant market share, followed by therapeutic devices and disposables. Market Trends and Drivers: Key market trends include the increasing adoption of home respiratory care, rising demand for non-invasive respiratory devices, and the integration of artificial intelligence and IoT. Drivers such as government initiatives to improve healthcare infrastructure, increasing awareness of respiratory diseases, and the expansion of the healthcare sector are fueling market growth. However, factors such as high costs and reimbursement challenges pose restraints on the market. Companies such as CHEST M I Inc, Terumo Corporation, and GE Healthcare are key players in the Japan respiratory devices industry. Recent developments include: Feb 2022: Aptar Pharma announced the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart, connected healthcare device., Mar 2021: PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announced the authorization of the LAMIRA Nebulizer System for delivery of Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan.. Key drivers for this market are: Increasing Prevalence of Respiratory Disorders, Technological Advancements in the Devices. Potential restraints include: High Cost of Equipment. Notable trends are: Inhalers Segment is Expected to Witness Strong Growth Over the Forecast Period.

The UK respiratory inhaler devices market is expected to grow steadily at a CAGR of 2.1% from 2025 to 2035 and reach USD 913.5 million by 2025.

Attribute	Details
Estimated Industry Size (2025F)	USD 913.5 million
Projected Industry Size (2035)	USD 1,117.1 million
Value CAGR (2025 to 2035)	2.1%

Tier-Wise Vendor Classification 2025

Vendor Tier	Tier 1
Key Vendors	GSK, AstraZeneca
Market Share (%)	55%
Description	Industry leaders with strong portfolios of inhalation therapies and devices.

Vendor Tier	Tier 2
Key Vendors	Philips Healthcare, Boehringer Ingelheim
Market Share (%)	30%
Description	Companies offering innovative nebulizers and digital inhaler solutions.

Vendor Tier	Tier 3
Key Vendors	Local manufacturers
Market Share (%)	15%
Description	Focus on generic products and cost-effective inhaler devices.

The size of the Smart Inhaler Technology Market was valued at USD 81.77 million in 2024 and is projected to reach USD 180.88 million by 2033, with an expected CAGR of 12.01% during the forecast period. The Smart Inhaler Technology Market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), along with the growing adoption of digital healthcare solutions. Smart inhalers integrate sensors and digital connectivity features to track medication usage, monitor adherence, and provide real-time data to patients and healthcare providers. Key components of smart inhalers include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers equipped with Bluetooth or other wireless communication technologies. These devices are designed to improve patient outcomes by reducing medication errors, enhancing adherence, and enabling remote monitoring through mobile applications and cloud-based platforms. North America dominates the market due to advanced healthcare infrastructure, high adoption of digital health solutions, and strong investments in respiratory care technologies. Europe follows closely, with increasing regulatory approvals for smart inhalers and growing awareness of digital therapeutics. The Asia-Pacific region is experiencing significant growth, driven by rising cases of respiratory disorders, expanding healthcare access, and increasing smartphone penetration. Challenges in the market include high costs, concerns regarding data privacy, and regulatory hurdles for digital health integration. However, continuous advancements in AI-driven analytics, telehealth integration, and personalized medicine are expected to drive market expansion. As the demand for remote patient monitoring and smart healthcare solutions rises, the smart inhaler technology market is poised for substantial growth.

According to Cognitive Market Research, the global respiratory trainers market size is USD 486.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 7.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 194.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 145.86 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 111.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD 24.31 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 9.72 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.
The asthma category held the highest respiratory trainers market revenue share in 2024.

Market Dynamics of Respiratory Trainers Market

Key Drivers of Respiratory Trainers Market

Rising Prevalence of Respiratory Illnesses to Increase the Demand Globally

The market for respiratory trainers is expanding as a result of the rising incidence of respiratory illnesses. Conditions that affect people of all ages, such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD), are becoming more commonplace worldwide. The rise in respiratory illnesses has prompted the creation and application of cutting-edge treatment options, such as respiratory trainers, to efficiently treat and lessen the symptoms of these illnesses. In pulmonary rehabilitation programs, respiratory trainers are essential because they provide patients with focused workouts that strengthen respiratory muscles, boost lung function, and improve overall respiratory health. Furthermore, the incorporation of digital elements for customized therapy and portable designs, among other technological improvements, enhance the usefulness and accessibility of respiratory trainers and lead to their growing popularity among patients and healthcare professionals.

Raising Consciousness of Respiratory Well-being to Propel Market Growth

One major factor driving the respiratory trainers market forward is rising awareness of respiratory health. There has been a noticeable upsurge in respiratory health-related public awareness campaigns, educational programs, and healthcare advocacy efforts in the last several years. The purpose of these campaigns is to raise awareness among the public about the significance of preserving normal respiratory function and skillfully treating respiratory disorders. Consequently, there is a rise in demand for respiratory trainers as people become more proactive in looking out ways to enhance their respiratory health. In pulmonary rehabilitation programs, these devices are essential because they assist patients build stronger respiratory muscles, increase lung function, and improve overall respiratory performance.

Restraint Factors Of Respiratory Trainers Market

Lac of Awareness among Individuals to Limit the Sales

One major obstacle to the respiratory trainers industry is the lack of knowledge about them. Many people, including patients and healthcare professionals, might not be completely aware of the presence or effectiveness of respiratory trainers, despite the rising prevalence of respiratory disorders and the advantages of respiratory muscle training. The use of respiratory trainers in preventive or pulmonary rehabilitation programs may be hampered by this lack of knowledge. Furthermore, understanding of the value of respiratory training may be especially low in areas with poor access to respiratory health education or healthcare services.

Impact of Covid-19 on the Respiratory Trainers Market

The market for respiratory trainers has been impacted by the COVID-19 epidemic in both positive and negative ways. Global industry and supply chain operations have been hampered by government lockdowns, travel restrictions, and other COVID-19 safety measures. This has had a detrimental effect on the respiratory trainer market worldwide. On the one hand, the market has grown as a result...

The respiratory inhaler devices market in Japan is expected to yield great gains accordingly. Between 2025 and 2035, its revenue will reach USD 2,961.0 million, with a 3.2% CAGR.

Attribute	Details
Projected Industry Size (2035F)	USD 2,961.0 million
Value CAGR (2025 to 2035)	3.2%

Tier-Wise Vendor Classification 2025

Vendor Tier	Tier 1
Key Vendors	GSK, AstraZeneca, Boehringer Ingelheim, Novartis Pharma AG
Market Share (%)	60%
Description	Dominant players offering innovative inhaler devices with strong global presence.

Vendor Tier	Tier 2
Key Vendors	Philips Healthcare, Takeda Pharmaceutical, CHIESI Farmaceutici S.p.A
Market Share (%)	30%
Description	Key contributors focusing on digital solutions and advanced nebulizer technologies.

Vendor Tier	Tier 3
Key Vendors	Local manufacturers(Daiichi Sankyo Company Ltd)
Market Share (%)	10%
Description	Providers of generic and cost-effective inhaler devices.

The global respiratory inhalers market is poised to experience substantial growth, projected to reach a market size of XX million by 2033, exhibiting a CAGR of 13.30% during the forecast period 2025-2033. This growth is primarily attributed to the rising prevalence of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), increasing awareness of respiratory health, and technological advancements in inhaler design and drug delivery systems. Moreover, the growing geriatric population, which is more susceptible to respiratory conditions, is further fueling market demand. Key market drivers include the increasing prevalence of respiratory diseases, advancements in inhaler technology, improving healthcare infrastructure, rising disposable income in developing countries, and favorable government initiatives to promote respiratory health. However, factors such as the high cost of branded inhalers, patent expiries, and stringent regulatory requirements may restrain market growth. The market is segmented based on product, application, type, and region. Key industry players include Pneuma Respiratory, Opko Health Inc., Trudell Medical UK Limited, Glenmark Pharmaceuticals, Novartis International AG, BreatheSuite Inc., Koninklijke Philips N.V., AptarGroup Inc., Amiko Digital Health Limited, Teva Pharmaceutical Industries Ltd., Propeller Health, and H&T Presspart Manufacturing Ltd. The global respiratory inhalers market is estimated to reach USD 40.3 Billion in 2028, witnessing a CAGR of 6.7% during the forecast period (2023-2028). The increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), is the primary factor driving the market growth. Other factors contributing to the market's growth include the development of innovative inhaler devices, the introduction of generic inhalers, and the growing awareness of respiratory diseases. Recent developments include: In February 2022 Astrazeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines., In February 2022, Aptar Pharma launched HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler into a smart connected healthcare device.. Key drivers for this market are: Rising Prevalence of Chronic Respiratory Diseases, Soaring Geriatric Population Afflicted With Respiratory Disorders; Increasing R&D Investment for Technological Improvement and Device Miniaturization. Potential restraints include: High Cost of the Devices. Notable trends are: Dry Powder Inhalers (DPI) are Expected to Hold a Major Share in the Growth of the Market Over the Forecast Period.

Introduction

Global Digital Patient Monitoring Devices Market size is expected to be worth around USD 1467 Billion by 2033, from USD 144.3 Billion in 2023, growing at a CAGR of 26.1% during the forecast period from 2024 to 2033. With a market share over 41.9%, North America held a strong lead in 2023, reaching US$ 60.4 Million in revenue.

The increasing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and respiratory ailments is driving the demand for digital patient monitoring devices. These devices enable continuous health tracking, which is essential for effective management and improved outcomes. Advances in wearable technology, including smartwatches and fitness trackers, have further facilitated remote health monitoring, enhancing patient care and minimizing the need for hospital visits.

The integration of artificial intelligence (AI) and machine learning into monitoring devices is transforming health data analysis. These technologies provide more precise insights, enabling personalized and proactive healthcare interventions. Additionally, the COVID-19 pandemic underscored the importance of remote patient monitoring to prevent disease spread and ensure efficient patient care, significantly accelerating market growth.

Despite its potential, the market faces challenges such as data privacy concerns and the high cost of advanced monitoring devices, which may limit their widespread use. Regulatory complexities and the need for continuous technological advancements also present hurdles to sustained growth.

Recent advancements include the development of AI-powered remote monitoring devices and increased government investment in digital health initiatives. A notable example is Abbott’s FDA clearance for the FreeStyle Libre 3 system in 2022, a compact glucose sensor that highlights ongoing innovation in the industry.

In conclusion, the Digital Patient Monitoring Devices Market is expected to grow significantly, driven by technological innovations, rising chronic disease rates, and supportive government initiatives. However, addressing challenges such as cost, privacy concerns, and regulatory barriers will be critical for maximizing its potential.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1067,h_714/https://market.us/wp-content/uploads/2024/04/Digital-Patient-Monitoring-Devices-Market-Regions.jpg" alt="Digital Patient Monitoring Devices Market Regions" class="wp-image-118829">

The size of the South Korea Respiratory Devices Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 7.80% during the forecast period. South Korea Respiratory Devices Market Increased incidence of respiratory diseases, such as asthma, COPD, and sleep apnea, in South Korea has resulted in high growth in the market. Contributing factors include urbanization, environmental pollution, and an aging population that triggers increasing demand for effective solutions to respiratory care. This involves other significant factors that develop the market, like technological breakthroughs, which later on results in developing new devices, such as respiratory devices, for instance, portable oxygen concentrators, nebulizers, and CPAP (continuous positive airway pressure), all of which mainly increase in smart technologies to enable remote monitoring and facilitate patient adherence to management of their respiratory diseases. Another key trend impacting the market is the growing demand for home health care. The evolution of coronavirus and even less capabilities have led most patients towards home-based management of their respiratory issues, and the shift has been significantly facilitated by the COVID-19 pandemic. It underlines the requirement for respirator devices that are not only user friendly but also effective to be used outside a clinical environment. Other government initiatives to enhance public health and increase access to health care resources are also included in market growth. South Korea has a robust healthcare system, which supports the use of advanced respiratory technology since patients are attended to promptly and correctly. Recent developments include: December 2022: LG launched an electronic face mask, LG Puricare Mask, in South Korea., May 2022: Somnics, Inc. received Korea Medical Device Registration and Approval (KFDA) for iNAP One Sleep Therapy System. In addition, the company launched its iNAP product in collaboration with LMT Korea Co. Ltd.. Key drivers for this market are: Increasing Prevalence of Respiratory Disorders, such as COPD, Asthma, and Sleep Apnea, Technological Advancements and Increasing Applications in Homecare Setting. Potential restraints include: High Cost of Devices. Notable trends are: Ventilator Segment is Expected to Register Significant Growth Over the Forecast Period.